Personalized mRNA Vaccine Shows Promise Against Melanoma in Landmark Trial

A five-year clinical trial has demonstrated that a personalized mRNA vaccine, when combined with the immunotherapy drug Keytruda, significantly reduces the risk of melanoma recurrence and improves survival. The vaccine is tailored to each patient's tumor, training the immune system to target unique cancer markers.

- 68.8% of patients receiving the combination remained cancer-free at five years, versus 49.1% with Keytruda alone. - The combination therapy reduced the risk of recurrence by 49%.

- 92% of combination therapy patients were alive at five years, compared to 71% on Keytruda alone. - Side effects were mild, including chills and injection site pain.

Researchers are now conducting a Phase 3 trial with nearly 1,000 patients, aiming for FDA approval. The approach is also being studied for other cancers, including lung cancer.